SOURCE: CEGEDIM STRATEGIC DATA

June 05, 2013 12:54 ET

Cegedim Strategic Data's Real-World Evidence Shows That Diabetes Management Varies Among the Top 5 European Countries

PARIS--(Marketwired - Jun 5, 2013) - Cegedim Strategic Data (CSD), leading provider of healthcare market research, has published the results of its study on Type 2 diabetes patients being treated with OADs (Oral antidiabetic drugs) or GLP-1 (Glucagon-like peptide agonists) treatments in France, Spain, Germany, Italy and the UK.

The study uses CSD's longitudinal patient databases which collect anonymised clinical data through electronic medical records (EMR) on a daily basis from its panel of physicians. This analysis was based on 415,093 Type 2 diabetes patients in the top 5 European countries (extrapolated to the national populations - 15.9 million patients), treated with OADs or GLP-1, by General Practitioners over one year (July 2011 - June 2012).

Result highlights

Between 4% and 6% of the population of the top 5 European countries are being treated for Type 2 diabetes with OADs or GLP-1 by their GP. In all five countries there are more males being treated than females with the above treatments. The average age of the patient being treated varies from 64.5 years in France to 69.6 years in Spain.

The predominant comorbidities associated with these diabetes patients in each of the countries are Hypertension (HTN - more commonly known as high blood pressure) and Dyslipidemia (Cholesterol). Over 85% of the patients in each of the countries analysed, were suffering from at least one of the main comorbidities associated with Diabetes.

France has the lowest percentage of diabetes patients categorized as obese (37.4%), whereas the UK shows the highest percentage (53.1%) followed closely by Germany (52.3%).

Germany has the highest percentage of patients (58.1%) who have their condition under control (HbA1c - level of blood sugar/glucose < 7%) compared to the lowest percentage among the five countries of 42.3% for the UK.

The above analyses demonstrate that disease management has an impact on public health and can vary significantly between countries even among those with mature healthcare systems.

About Cegedim Strategic Data:
Cegedim Strategic Data (CSD) is a leading market research company dedicated to the healthcare industry and operating worldwide.
With over 40 years' experience in the pharmaceutical industry, Cegedim Strategic Data offers a comprehensive range of market research services and solutions to its customers, which include more than 50 global and 500 local pharmaceutical companies. CSD integrates primary and secondary analyses with its medical expertise to meet its customer's research needs. To learn more, please visit our website: www.cegedimstrategicdata.com and follow Cegedim Strategic Data on Twitter @CSDCegedim.

About Cegedim: 
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,100 people in more than 80 countries and generated revenue of EUR 922 million in 2012. Cegedim SA is listed in Paris (EURONEXT PARIS: CGM).
To learn more, please visit: www.cegedim.com and follow Cegedim on Twitter: @CegedimGroup.

CSD RWE Diabetes Top5EU: http://hugin.info/141732/R/1707014/565205.pdf

Contact Information